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Background: Hospitalization is a costly and distressing event associated with relapse during schizophrenia treatment.
No information is available on the predictors of psychiatric hospitalization during maintenance treatment with
olanzapine long-acting injection (olanzapine-LAI) or how the risk of hospitalization differs between olanzapine-LAI and
oral olanzapine. This study aimed to identify the predictors of psychiatric hospitalization during maintenance treatment
with olanzapine-LAI and assessed four parameters: hospitalization prevalence, incidence rate, duration, and the time to
first hospitalization. Olanzapine-LAI was also compared with a sub-therapeutic dose of olanzapine-LAI and with oral
olanzapine.
Methods: This was a post hoc exploratory analysis of data from a randomized, double-blind study comparing the
safety and efficacy of olanzapine-LAI (pooled active depot groups: 405 mg/4 weeks, 300 mg/2 weeks, and 150 mg/2
weeks) with oral olanzapine and sub-therapeutic olanzapine-LAI (45 mg/4 weeks) during 6 months’ maintenance
treatment of clinically stable schizophrenia outpatients (n=1064). The four psychiatric hospitalization parameters were
analyzed for each treatment group. Within the olanzapine-LAI group, patients with and without hospitalization were
compared on baseline characteristics. Logistic regression and Cox’s proportional hazards models were used to identify
the best predictors of hospitalization. Comparisons between the treatment groups employed descriptive statistics, the
Kaplan–Meier estimator and Cox’s proportional hazards models.
Results: Psychiatric hospitalization was best predicted by suicide threats in the 12 months before baseline and by prior
hospitalization. Compared with sub-therapeutic olanzapine-LAI, olanzapine-LAI was associated with a significantly lower
hospitalization rate (5.2% versus 11.1%, p < 0.01), a lower mean number of hospitalizations (0.1 versus 0.2, p = 0.01),
a shorter mean duration of hospitalization (1.5 days versus 2.9 days, p < 0.01), and a similar median time to first
hospitalization (35 versus 60 days, p = 0.48). Olanzapine-LAI did not differ significantly from oral olanzapine on the
studied hospitalization parameters.
Conclusions: In clinically stable schizophrenia outpatients receiving olanzapine-LAI maintenance treatment, psychiatric
hospitalization was best predicted by a history of suicide threats and prior psychiatric hospitalization. Olanzapine-LAI
was associated with a significantly lower incidence of psychiatric hospitalization and shorter duration of hospitalization
compared with sub-therapeutic olanzapine-LAI. Olanzapine-LAI did not differ significantly from oral olanzapine on
hospitalization parameters.
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Schizophrenia is a chronic condition in which relapses
are likely to occur throughout the patient’s life [1,2].
During a relapse, the patient may need to be admitted to
hospital for acute treatment to bring psychotic symp-
toms under control. Psychiatric hospitalizations and es-
pecially re-hospitalizations are linked to poor outcomes
and a delayed or reduced likelihood of recovery [3]. In a
meta-analysis of published reports on rehospitalization,
Weiden and Olfson [4] estimated that 50% of patients
treated with typical antipsychotics would be readmitted
within 1 year, and about 80% of patients would be re-
admitted by 2 years. In additional to increasing the per-
sonal burden on patients and family members along
with disruption of outpatient rehabilitation plans,
hospitalization is also costly in economic terms, as the
cost of hospitalization accounts for the largest share of
treatment costs in schizophrenia [5,6].
Loss (or lack) of medication efficacy and medication
non-adherence tend to act synergistically to increase the
risk of relapse and hospitalization. Even in patients re-
ceiving continuous medication, it has been estimated
that 3.5% of patients will relapse per month, and this
rate increases to 11% per month among non-adherent
patients [3]. Substantial inpatient hospitalization cost
savings can thus be realized by linking better pharmaco-
logical treatments with more effective strategies to
manage medication non-adherence in the management
of patients with schizophrenia [3,7]. High severity of
positive symptoms, lack of insight, not living with the
family, frequent past episodes, addiction to illegal drugs,
and global illness severity have all been associated with a
higher risk of hospitalization [8]. Suicide behavior, which
may be present in over 50% of patients [9] and may
cause a 10–13% mortality rate in schizophrenia [10], is
also associated with a high risk of hospitalization, as
hospitalization is a frequent treatment intervention for
suicidal patients.
Prior research has shown differential rates of psychiatric
hospitalization among oral antipsychotics, as clozapine
and olanzapine were found to be associated with a lower
rehospitalization rate compared with other oral antipsy-
chotics [11,12]. Long-acting injection (LAI, depot) anti-
psychotic formulations are recommended for the
treatment of non-adherent patients [13], as depot medica-
tions ensure adherence during the injection duration and
may help reduce the risk of relapse [14-16]. It has been
reported that LAI formulations can reduce the risk of re-
lapse in patients with adherence difficulties [17]. The com-
parative effectiveness of oral vs. LAI antipsychotics in
reducing patients’ relapse and hospitalization rates has
been a topic of controversy. A recent literature review and
meta-analysis [18] found that LAI antipsychotics were as-
sociated with a lower risk of relapse but the limited dataon hospitalization did not reveal significant differences
between the two formulations. These findings, along with
other recent publications [19,20], help highlight that the
lack of observed differences in treatment outcomes
between oral and LAI antipsychotics may be driven by
reliance on randomized clinical trials, which tend not to
enroll non-adherent schizophrenia patients, the very
group of patients for whom LAI antipsychotics are most
appropriate.
The long-acting formulation of olanzapine is available for
the treatment of patients with schizophrenia and its safety
and efficacy have been shown previously [21,22]. However,
no information is available on the predictors of hospita-
lization during treatment with olanzapine-LAI or how the
risk of hospitalization differs between olanzapine-LAI and
placebo in the maintenance phase of schizophrenia.
Using data from a 24-week, randomized, double-blind
study that compared the safety and efficacy of
olanzapine-LAI with oral olanzapine and a placebo-like,
sub-therapeutic dose of olanzapine-LAI [22], this post
hoc analysis aimed to: (a) identify the predictors of psy-
chiatric hospitalization in the maintenance treatment of
schizophrenia patients with olanzapine-LAI, and (b) as-
sess four hospitalization parameters (the prevalence of
hospitalization, its incidence rate, duration, and time to
first hospitalization) and compare olanzapine-LAI with a
placebo-like, sub-therapeutic dose of olanzapine-LAI
and oral olanzapine on these hospitalization parameters.
Methods
Study design
This multicenter study was conducted by 113 investigators
at 112 study sites in 26 countries. The countries which par-
ticipated in the study were Spain, France, Sweden, Norway,
Austria, Belgium, Finland, Netherlands, Germany, Portugal,
Italy, Russia, Hungary, Turkey, Greece, Romania, Poland,
Israel, Argentina, Brazil, Puerto Rico, United States, Mexico,
Australia, South Africa, and Taiwan.
Patients included in the study had a schizophrenia
diagnosis according to DSM-IV or DSM-IV-TR and were
aged 18 to 75 years. Patients had to have maintained
outpatient status and be judged by investigators (based
on clinical interview and impression) to have been stable
(with respect to their schizophrenia symptoms) for at
least 4 weeks before study entry. Patients also had to
have Brief Psychiatric Rating Scale (BPRS) positive items
≤4 (on a scale of 1 to 7) at the time of study entry.
The study had an open-label stabilization phase (4–8
weeks) followed by a double-blind randomized phase (24
weeks). During the stabilization phase, all patients were
switched to open-label oral olanzapine monotherapy at a
dose of 10, 15 or 20 mg/day. Patients who met the
stabilization criteria were randomly assigned to double-
blind therapy with one of the following five treatments:
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medium-dose olanzapine-LAI (405 mg/4 weeks, n =
318), high-dose olanzapine-LAI (300 mg/2 weeks, n =
141), oral olanzapine (a stabilized dose of oral
olanzapine, 10, 15 or 20 mg/day n = 322) and a sub-
therapeutic (very low) dose of olanzapine-LAI (45 mg/4
weeks, n = 144).
Patients were assessed using the Positive and Negative
Syndrome Scale (PANSS) [23], the Clinical Global
Impressions-Severity of Illness scale (CGI-S) [24], the
Health Outcomes Form [25] (which assesses work sta-
tus, living conditions, functional activities and suicide
threats), the Drug Attitude Inventory (DAI-10) [26], the
Hospitalization Inventory, and the Medical Outcomes
Study Short-Form 36-item version (SF-36) [27].
The study protocol was approved by institutional review
boards at each site. After receiving a complete description
of the study, all patients and/or their authorized legal rep-
resentatives provided written informed consent before
participation. A complete description of the methods can
be found in the main study publication [22].
Variables
Patients who were included in the double-blind, ran-
domized phase and who had baseline data and at least
one post-baseline assessment during follow up were in-
cluded in the analysis (n = 1064). Data for patients in
the three olanzapine-LAI active medication groups (low-
dose olanzapine-LAI, medium-dose olanzapine-LAI, and
high-dose olanzapine-LAI) were pooled into a single
olanzapine-LAI group. The duration of each psychiatric
hospitalization (based on data in the Hospitalization In-
ventory) was calculated as the discharge date minus the
admission date plus one.
Patients with and without a psychiatric hospitalization
during the study period were first compared on the fol-
lowing 16 baseline variables: sex, age, age at illness on-
set, any suicide threat before baseline (in the 12 months
before baseline), PANSS total score, CGI-S score, DAI
total score, working for pay, living independently, func-
tional impairment, geographical region, tobacco use,
body mass index, psychiatric outpatient visits before
baseline, health related quality of life (SF-36 score), and
the presence of a prior hospitalization.
Statistical analysis
The p values for group comparisons were calculated
using the Chi-square test for categorical variables and
the Wilcoxon-Mann and Whitney test for numerical
variables.
The Kaplan–Meier product limit estimation method
was used to compare time to first hospitalization for the
three treatment groups. Regression models were built to
identify the baseline factors associated with subsequentpsychiatric hospitalization; a logistic regression model
was used for analysis of psychiatric hospitalization
during the study period, and Cox’s proportional hazards
model was used for analysis of time to first psychiatric
hospitalization.
The regression models included as covariates the base-
line variables that were found to differ significantly
between patients with psychiatric hospitalization versus
those without psychiatric hospitalization in the descrip-
tive analysis. These variables were: sex, age of the pa-
tient, any suicide threat before baseline, previous
hospitalization, age at illness onset, PANSS total score,
and DAI total score. To take into consideration varia-
tions in healthcare utilization across regions, the regres-
sion models were adjusted by geographical region
(Western Europe, Eastern Europe, America, Other).
All analyses were performed using SAS, version 9.1
(SAS Institute, Inc., Cary, NC).
Results
Patient characteristics at baseline by treatment group are
summarized in Table 1. Of the 1064 patients included in
this study, 598 were treated with olanzapine-LAI, 322
with oral olanzapine and 144 with sub-therapeutic
olanzapine-LAI. There were no statistically significant
differences between the groups on any of the baseline
sociodemographic or clinical characteristics.
Among all study participants, the percentage of hospi-
talized patients was slightly higher for males than fe-
males (5.8% versus 5.5%, not significant). The mean age
of the patients who were hospitalized was 42.1 (SD 9.6)
years compared with 38.8 (SD 11.4) years for those not
hospitalized (p = 0.02). Mean age of onset was very simi-
lar at 25.6 years (SD 7.4) for those hospitalized versus
25.7 years (SD 8.4) for those not hospitalized. The mean
PANSS total score of the hospitalized group was 52.2
(SD 16.2) compared with 56.1 (SD 15.5) for the non-
hospitalized group (p = 0.05). Mean CGI-S scores for pa-
tients with versus without hospitalization were nearly
identical; 3.08 (SD 0.9) for patients who were hospital-
ized and 3.07 (SD 0.9) for those who were not, while
mean DAI scores of the hospitalized group were 7.9 (SD
1.6) versus 7.4 (SD 1.8) for those without hospitalization
(p = 0.01). In terms of type of olanzapine therapy, the
rate of hospitalization was higher for patients in the sub-
therapeutic olanzapine-LAI (11.1% hospitalized) com-
pared with olanzapine-LAI and oral olanzapine groups
(5.2% and 4.0%, respectively) (p < 0.01). A total of 14.7%
of patients who had threatened suicide were hospitalized
compared with 5.3% of those who did not threaten sui-
cide (p = 0.04). Finally, previous hospitalization was
strongly related to hospitalization during follow up; the
percentage of patients admitted during follow up was
4.6% among patients with no previous hospitalizations







Male (%) 65.2 66.7 64.9
Working for pay (%) 20.5 18.1 14.1
Living independently (%) 21.2 17.4 18.8
At least one functional activity (%) 83.6 77.1 83.8
Any suicide threat (%) 3.4 5.6 1.9
Prior psychiatric hospitalization (%) 4.68 6.94 4.97
Current tobacco use (%) 48.1 49.3 49.8
Geographical region (%)
America 29.8 31.3 31.4
Eastern Europe 30.1 29.2 29.2
Western Europe 29.8 27.8 30.1
Other 10.4 11.8 9.3
Age in years, mean (SD) 38.8 (11.1) 39.5 (11.6) 39.0 (11.6)
Age at onset, years, mean (SD) 25.6 (8.0) 26.1 (9.2) 25.6 (8.4)
Body mass index (BMI), kg/m2, mean (SD) 26.5 (5.1) 26.8 (5.2) 26.4 (5.1)
PANSS total, mean (SD) 55.4 (15.5) 57.8 (15.9) 56.1 (15.6)
CGI-S score, mean (SD) 3.1 (0.9) 3.2 (0.9) 3.1 (1.0)
DAI score, mean (SD) 7.4 (1.8) 7.3 (1.9) 7.5 (1.7)
SF-36 physical score, mean (SD) 49.4 (8.2) 48.5 (8.7) 49.7 (8.1)
SF-36 mental score, mean (SD) 42.7 (11.1) 42.9 (11.8) 43.1 (11.9)
Psychiatric outpatient visits before baseline, mean (SD) 10.2 (10.1) 9.5 (10.2) 9.7 (10.4)
CGI-S Clinical Global Impression-Severity, DAI Drug Attitude Inventory, LAI long-acting injection, PANSS Positive and Negative Symptom Score, SF-36 Medical Outcomes
Study Short-Form 36-item version, SD, standard deviation.
aAll p values for treatment group comparisons were greater than 0.05.
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(p < 0.001).
Table 2 presents the hospitalization parameters by treat-
ment group. Compared with sub-therapeutic olanzapine-
LAI, olanzapine-LAI was associated with a significantly
lower hospitalization rate (5.2% versus 11.1%, p < 0.01), a
lower mean number of hospitalizations (0.1 versus 0.2, p =
0.01), and a shorter mean duration of hospitalization (1.5Table 2 Psychiatric hospitalization parameters by treatment g




Hospitalization rate, % 5.2 11.1 4.0
Number of hospitalizations,
mean (SD)
0.1 (0.4) 0.2 (0.6) 0.1 (0.
Number of days hospitalized,
mean (SD)b
1.5 (12.26) 2.9 (15.03) 2.3 (17
CGI-S Clinical Global Impression-Severity, DAI Drug Attitude Inventory, PANSS Positive a
ap values calculated using Chi-square and t-tests.
bCalculation of the mean number of days includes both patients hospitalized and n
patients divided by total number of patients in the group).days versus 2.9 days, p < 0.01). The treatment groups
did not differ significantly on median time to first
hospitalization among hospitalized patients (35 days for
sub-therapeutic olanzapine-LAI versus 60 days for
olanzapine-LAI, p = 0.48). Olanzapine-LAI did not differ
significantly from oral olanzapine on the studied hospitali-
zation parameters. The Kaplan-Meier figure (Figure 1)













5) 0.0092 0.4385 0.0038
.2) 0.0084 0.4639 0.0041
nd Negative Symptom Score, LAI long-acting injection, SD standard deviation.
ot hospitalized (calculation is number of days in the hospital including all
Figure 1 Time (days) to psychiatric hospitalization by treatment group: olanzapine-LAI, sub-therapeutic olanzapine-LAI, and oral olanzapine.
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hospitalized and time to first hospitalization. In con-
trast, the percentage of patients hospitalized was higher
and time to first hospitalization was shorter among pa-
tients treated with sub-therapeutic olanzapine-LAI.
The findings of the regression models are presented in
Table 3. Baseline factors that were significantly associ-
ated with hospitalization in the olanzapine-LAI group
were: prior suicide threats with an odds ratio (OR) of 7.1
(95% CI: 2.2; 23.0), and previous hospitalization with an
OR of 5.84 (95% CI: 1.92; 17.78).
The Cox regression model found that patients receiving
sub-therapeutic olanzapine-LAI had a significantly shorter
time to first psychiatric hospitalization compared withTable 3 Findings from regression models: baseline variables a
Factors associated with





Female 0.81 (0.35; 1.87)
Age 0.99 (0.94; 1.05)
Suicide threats 7.09 (2.19; 23.01)
Previous hospitalization 5.84 (1.92; 17.78)
Age at onset 1.03 (0.97; 1.09)
Total PANSS score 0.98 (0.96; 1.01)
DAI score 0.91 (0.72; 1.15)
Values are odds ratio (95% confidence interval).
DAI Drug Attitude Inventory, PANSS Positive and Negative Symptom Score, LAI longpatients receiving olanzapine-LAI (hazard rate 0.75 versus
2.41). Other statistically significant baseline factors associ-
ated with a shorter time to hospitalization among
patients in the olanzapine-LAI group were higher PANSS
score, prior suicide threats and previous psychiatric
hospitalization.
Discussion
This post hoc analysis found that during the 6-month
maintenance treatment of schizophrenia patients with
olanzapine-LAI, psychiatric hospitalization was best pre-
dicted by suicide threats at baseline and by prior psychi-
atric hospitalization. Suicide threats were strongly
associated with future hospitalization even after takingssociated with psychiatric hospitalization
reatment group/regression model
All patients/logistic regression All patients/Cox regression
0.78 (0.39; 1.58) 0.75 (0.39; 1.45)
2.34 (1.18; 4.65) 2.41 (1.29; 4.52)
0.77 (0.42; 1.42) 0.70 (0.39; 1.23)
1.01 (0.98; 1.05) 1.02 (0.98 ;1.05)
3.63 (1.26; 10.46) 3.76 (1.44; 9.83)
5.54 (2.50; 12.27) 5.18 (2.62; 10.21)
1.02 (0.99; 1.06) 1.02 (0.99; 1.05)
0.98 (0.96; 0.99) 0.98 (0.96; 0.99)
1.12 (0.93; 1.35) 1.10 (0.93; 1.32)
-acting injection, NA not applicable.
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Current findings are consistent with prior research
showing that suicide threats are one of the main causes
of hospitalization in schizophrenia patients [28] and tend
to predict future hospitalization [29].
As expected, past hospitalization was strongly associated
with future hospitalization. A number of other schizophre-
nia studies have also found this association [30-32], re-
flecting a known general phenomenon where past behavior
tends to be a robust predictor of future behavior [33].
In the current analysis, symptom severity at baseline
was only weakly associated with the risk of hospitalization.
Although some studies have found symptom severity at
baseline to be associated with hospitalization, others have
not [1]. It is possible that findings differ because the asso-
ciation depends on the point at which symptoms are
assessed in the course of the illness; in the current study,
patients were assessed when their symptoms were rela-
tively mild and clinically stable.
As for the study’s second objective, this post hoc analysis
found that compared with placebo-like sub-therapeutic
olanzapine-LAI, treatment with olanzapine-LAI was as-
sociated with a significantly lower rate of psychiatric
hospitalization (5.2% versus 11.1%), a lower incidence of
hospitalization during follow up (0.1 versus 0.2) and a
shorter duration of hospitalization among hospitalized pa-
tients (1.5 days versus 2.9 days). This finding is consistent
with a recent meta-analysis that found that treatment with
antipsychotics confers a significantly greater relapse
prevention compared with placebo in the treatment of
schizophrenia [34].
The risk of hospitalization – as assessed here using
four hospitalization parameters – however, was not
found to differ significantly between the oral and LAI
formulations of olanzapine. This finding is likely driven
by the study design, a randomized clinical trial (RCT) of
stable, mildly ill and mostly adherent outpatients. In this
sample, the hospitalization rate was relatively low, which
lowers the power of finding significant findings. Al-
though non-adherent patients are typically the ones
chosen for depot formulations in clinical practice, they
are often reluctant to enroll in RCTs. This interpretation
seems consistent with a recent study that found
differences in effectiveness when comparing results from
RCTs and observational studies, with observational
studies finding larger medication differences [20]. A
large review of RCTs comparing oral with LAI treatment
found significant differences in relapse rates between
RCTs of depot and oral antipsychotics, but did not find
differences in hospitalization rates or other outcome pa-
rameters [18]. As mentioned above, naturalistic studies
have shown differences in hospitalization rates between
oral and depot formulations. For example, Tiihonen and
colleagues conducted retrospective analyses of Finnishdatabases and found depot therapy to be associated with
a significantly lower risk of hospital admission compared
with oral formulations of the same compounds [11,12].
In another similar study in Hungary, depot antipsy-
chotics were found to have a lower hospitalization
rate than many other oral antipsychotics [19]. Similar
findings were observed in the Schizophrenia Outpatients
Health Outcomes (SOHO) Study [35], a large pan-
European, naturalistic, prospective, observational study
of schizophrenia patients. That analysis of SOHO fo-
cused on non-adherent patients who were initiated on
typical antipsychotics in oral or depot formulations (n =
431) and found that patients initiated on depot formula-
tions had a significantly lower rate of hospitalization and
a lower mean number of hospitalizations following 6
months of treatment. The potential confounding impact
of clinical trials versus naturalistic practice settings will
require further research to clarify the relative advantage
of depot versus oral atypical antipsychotics in reducing
the risk of hospitalization among patients with schizo-
phrenia. Observational studies may be better suited to
study the impact of depot therapy on treatment out-
comes among non-adherent patients because these pa-
tients tend not to participate in RCTs.
Current findings need to be evaluated in the context of
the study limitations. Firstly, this post hoc analysis used
data from an RCT with the primary objective of comparing
olanzapine-LAI, oral olanzapine and sub-therapeutic
olanzapine-LAI on time to exacerbation of symptoms of
schizophrenia in clinically stable patients who were first
stabilized on oral olanzapine [22]. Thus, as all patients were
first stabilized on oral olanzapine and their baseline PANSS
scores were within the mildly ill range, the chances of
finding differences between the oral and depot formulations
of olanzapine were much reduced. This may also explain
the relatively low hospitalization rate observed in the study.
Moreover, participants in the depot treatment arm were
randomly assigned to switch from oral olanzapine to
olanzapine-LAI, whereas those in the oral treatment arm
got to stay on their preferred stabilized doze of oral
olanzapine, suggesting that study design may have been
biased against depot patients. Secondly, this study (like
most RCTs) included a low percentage of patients who
were non-adherent with treatment, although these are
typically the target patients for depot therapy in usual care.
Thus these findings may not generalize to treatment with
olanzapine-LAI in naturalistic care settings.
Conclusion
In this 6-month maintenance study, psychiatric hospi-
talization was best predicted by previous suicide threats
and prior psychiatric hospitalization, two predictors that
were previously observed with oral antipsychotic therapy
in the treatment of schizophrenia. In addition, olanzapine-
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cantly lower psychiatric hospitalization rate, a lower
mean number of hospitalizations, and a shorter mean
hospitalized duration compared with sub-therapeutic
olanzapine-LAI. Olanzapine-LAI did not differ signifi-
cantly from oral olanzapine on these hospitalization
parameters, likely reflecting the impact of the study’s
design.
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